Comprehensive Treatment Uncertainty Analysis and PTV Margin Estimation for Fiducial Tracking in Robotic Liver Stereotactic Body Radiation Therapy

Abstract

Objective

This study aims to quantify the uncertainties of CyberKnife Synchrony fiducial tracking for liver stereotactic body radiation therapy (SBRT) cases, and evaluate the required planning target volume (PTV) margins.

Methods

A total of 11 liver tumor patients with a total of 57 fractions, who underwent SBRT with synchronous fiducial tracking, were enrolled for the present study. The correlation/prediction model error, geometric error, and beam targeting error were quantified to determine the patient-level and fraction-level individual composite treatment uncertainties. The composite uncertainties and multiple margin recipes were compared for scenarios with and without rotation correction during treatment.

Results

The correlation model error-related uncertainty was 4.3±1.8, 1.4±0.5 and 1.8±0.7 mm in the superior-inferior (SI), left-right, and anterior-posterior directions, respectively. These were the primary contributors among all uncertainty sources. The geometric error significantly increased for treatments without rotation correction. The fraction-level composite uncertainties had a long tail distribution. Furthermore, the generally used 5-mm isotropic margin covered all uncertainties in the left-right and anterior-posterior directions, and only 75% of uncertainties in the SI direction. In order to cover 90% of uncertainties in the SI direction, an 8-mm margin would be needed. For scenarios without rotation correction, additional safety margins should be added, especially in the superior-inferior and anterior-posterior directions.

Conclusion

The present study revealed that the correlation model error contributes to most of the uncertainties in the results. Most patients/fractions can be covered by a 5-mm margin. Patients with large treatment uncertainties might need a patient-specific margin.

Keywords

CyberKnife / fiducial tracking / liver cancer / stereotactic body radiation therapy / margin expansion

References

[1] Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. IARC, 2020

[2] GoyalK, EinsteinD, YaoM, et al.. Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: preliminary results. HPB Surg, 2010, 2010: 309780

[3] ClericiE, ComitoT, FranzeseC, et al.. Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors. Strahlenther Onkol, 2020, 196(4): 325-333

[4] DobrzyckaM, SpychalskiP, RostkowskaO, et al.. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome. Acta Oncol, 2019, 58(12): 1706-1713

[5] GoodmanKA, KavanaghBD. Stereotactic Body Radiotherapy for Liver Metastases. Semin Radiat Oncol, 2017, 27(3): 240-246

[6] LiangZ, LiuH, XueJ, et al.. Evaluation of the intra- and interfractional tumor motion and variability by fiducial-based real-time tracking in liver stereotactic body radiation therapy. J Appl Clin Med Phys, 2018, 19(3): 94-100

[7] KilbyW, DooleyJR, KuduvalliG, et al.. The CyberKnife Robotic Radiosurgery System in 2010. Technol Cancer Res Treat, 2010, 9(5): 433-452

[8] SunJ, OuyangC, ChangXY, et al.. Repeated CyberKnife stereotactic body radiation therapy in hepatocellular carcinoma. Radiat Oncol, 2020, 15(1): 10

[9] YuanZY, MengMB, LiuCL, et al.. Stereotactic body radiation therapy using the CyberKnife^® system for patients with liver metastases. Oncotargets Ther, 2014, 7: 915-923

[10] SunJ, ZhangAM, LiWG, et al.. CyberKnife Stereotactic Body Radiation Therapy as an Effective Treatment for Hepatocellular Carcinoma Patients With Decompensated Cirrhosis. Front Oncol, 2020, 10: 100

[11] AmbrosinoG, PolistinaF, CostantinG, et al.. Image-guided Robotic Stereotactic Radiosurgery for Unresectable Liver Metastases: Preliminary Results. Anticancer Res, 2009, 29(8): 3381-3384

[12] GoodmanKA, WiegnerEA, MaturenKE, et al.. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys, 2010, 78(2): 486-493

[13] StintzingS, HoffmannRT, HeinemannV, et al.. Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. Eur J Cancer, 2010, 46(6): 1026-1032

[14] Vautravers-DewasC, DewasS, BonodeauF, et al.. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship?. Int J Radiat Oncol Biol Phys, 2011, 81(3): e39-47

[15] PepinEW, WuH, ZhangY, et al.. Correlation and prediction uncertainties in the cyberknife synchrony respiratory tracking system. Med Phys, 2011, 38(7): 4036-4044

[16] ZhenX, ZhaoB, WangZ, et al.. Comprehensive target geometric errors and margin assessment in stereotactic partial breast irradiation. Radiat Oncol, 2017, 12(1): 151

[17] WinterJD, WongR, SwaminathA, et al.. Accuracy of Robotic Radiosurgical Liver Treatment Throughout the Respiratory Cycle. Int J Radiat Oncol Biol Phys, 2015, 93(4): 916-924

[18] LiuM, CyglerJE, VandervoortE. Geometrical tracking accuracy and appropriate PTV margins for robotic radiosurgery of liver lesions by SBRT. Acta Oncol, 2019, 58(6): 906-915

[19] Hasse K, Han F, Neylon J, et al. Estimation and validation of patient-specific liver elasticity distributions derived from 4DMR for radiotherapy purposes. Biomed Phys Eng Expr, 2018,4(4)

[20] WormES, BertholetJ, HoyerM, et al.. Fiducial marker guided stereotactic liver radiotherapy: Is a time delay between marker implantation and planning CT needed?. Radiother Oncol, 2016, 121(1): 75-78

[21] ValentineK, CabreraT, RobergeD. Implanting metal fiducials to guide stereotactic liver radiation: McGill experience and review of current devices, techniques and complications. Technol Cancer Res Treat, 2014, 13(3): 253-258

[22] OzhasogluC, SawCB, ChenH, et al.. Synchrony-cyberknife respiratory compensation technology. Med Dosim, 2008, 33(2): 117-123

[23] PaulssonAK, YomSS, AnwarM, et al.. Respiration-Induced Intraorgan Deformation of the Liver: Implications for Treatment Planning in Patients Treated With Fiducial Tracking. Technol Cancer Res Treat, 2017, 16(6): 776-782

[24] LiangZ, ZhouQ, YangJ, et al.. Artificial intelligence-based framework in evaluating intrafraction motion for liver cancer robotic stereotactic body radiation therapy with fiducial tracking. Med Phys, 2020, 47(11): 5482-5489

[25] VandervoortE, PatrocinioH, ChowT, et al.. COMP Report: CPQR technical quality control guidelines for CyberKnife^® Technology. J Appl Clin Med Phys, 2018, 19(2): 29-34

[26] FlorianoA, GarcãaR, MorenoR, et al.. Retrospective evaluation of CTV to PTV margins using CyberKnife in patients with thoracic tumors. J Appl Clin Med Phys, 2014, 15(6): 4825

[27] ZhangJ, WangL, LiX, et al.. Quantification of Intrafraction and Interfraction Tumor Motion Amplitude and Prediction Error for Different Liver Tumor Trajectories in Cyberknife Synchrony Tracking. Int J Radiat Oncol Biol Phys, 2021, 109(5): 1588-1605

[28] ChanM, GrehnM, CremersF, et al.. Dosimetric Implications of Residual Tracking Errors During Robotic SBRT of Liver Metastases. Int J Radiat Oncol Biol Phys, 2017, 97(4): 839-848

[29] ErnstF, SchlaeferA, SchweikardA. Smoothing of respiratory motion traces for motion-compensated radiotherapy. Med Phys, 2010, 37(1): 282-294

[30] NakayamaM, UeharaK, NishimuraH, et al.. Retrospective assessment of a single fiducial marker tracking regimen with robotic stereotactic body radiation therapy for liver tumors. Rep Pract Oncol Radiother, 2019, 24(4): 383-391

[31] LiuM, CyglerJE, VandervoortE. Patient-specific PTV margins for liver stereotactic body radiation therapy determined using support vector classification with an early warning system for margin adaptation. Med Phys, 2020, 47(10): 5172-5182

[32] LiangZ, YangJ, LiuH, et al.. Real-time tumor motion monitoring and PTV margin determination in lung SBRT treatment. Acta Oncol, 2019, 58(12): 1786-1789